Peringatan Keamanan

LD50 information for dulaglutide is not readily available in the literature.L34685 Cases of overdose with dulaglutide have resulted in gastrointestinal disturbance. Appropriate supportive treatment is recommended to manage signs and symptoms.L34670 Additionally, hypoglycemia has been observed after an overdose with dulaglutide; frequent plasma glucose monitoring should be performed.L30380

Dulaglutide

DB09045

biotech approved investigational

Deskripsi

Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM).A236070 Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.L34665

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) In a pharmacokinetic study of 20 healthy adults, the average half-life of dulaglutide administered at various doses was approximately 3.75 days (89.9 hours). This extended half-life allows for once-weekly dosing.[A234419] Prescribing information indicates a half-life of approximately 5 days.[L30380]
Volume Distribusi The apparent volume of distribution of dulaglutide was 3.09 L in a pharmacokinetic study; the apparent population mean peripheral volume of distribution was approximately 6 L.[L30380]
Klirens (Clearance) The apparent population mean clearance of dulaglutide was 0.142 L/h in a pharmacokinetic study.[L30380]

Absorpsi

Dulaglutide is slowly absorbed after subcutaneous injection.L34670 In a pharmacokinetic study of 20 healthy adults, Cmax occurred within 24-48 hours after dosing.A234419 The average absolute bioavailability of dulaglutide after subcutaneous injections of single 0.75 mg and 1.5 mg doses was 65% and 47%, respectively.L30380

Metabolisme

Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways.L30380

Rute Eliminasi

Elimination of dulaglutide is expected to occur through degradation to individual amino acids.L30380

Interaksi Makanan

1 Data
  • 1. Take with or without food.

Interaksi Obat

968 Data
Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dulaglutide.
Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Dulaglutide.
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Dulaglutide.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Dulaglutide.
Conjugated estrogens The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Conjugated estrogens.
Estrone Estrone may increase the thrombogenic activities of Dulaglutide.
Dienestrol Dienestrol may increase the thrombogenic activities of Dulaglutide.
Estriol Estriol may increase the thrombogenic activities of Dulaglutide.
Quinestrol Quinestrol may increase the thrombogenic activities of Dulaglutide.
Hexestrol Hexestrol may increase the thrombogenic activities of Dulaglutide.
Tibolone Tibolone may increase the thrombogenic activities of Dulaglutide.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dulaglutide.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dulaglutide.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Dulaglutide.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Dulaglutide.
Zeranol Zeranol may increase the thrombogenic activities of Dulaglutide.
Equol Equol may increase the thrombogenic activities of Dulaglutide.
Promestriene Promestriene may increase the thrombogenic activities of Dulaglutide.
Methallenestril Methallenestril may increase the thrombogenic activities of Dulaglutide.
Epimestrol Epimestrol may increase the thrombogenic activities of Dulaglutide.
Moxestrol Moxestrol may increase the thrombogenic activities of Dulaglutide.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Dulaglutide.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Dulaglutide.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Dulaglutide.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Dulaglutide.
Biochanin A Biochanin A may increase the thrombogenic activities of Dulaglutide.
Formononetin Formononetin may increase the thrombogenic activities of Dulaglutide.
Estradiol The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Estradiol.
Moxifloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Moxifloxacin.
Grepafloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Grepafloxacin.
Enoxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Enoxacin.
Pefloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Pefloxacin.
Ciprofloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Ciprofloxacin.
Trovafloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Trovafloxacin.
Nalidixic acid The therapeutic efficacy of Dulaglutide can be increased when used in combination with Nalidixic acid.
Rosoxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Rosoxacin.
Cinoxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Cinoxacin.
Lomefloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Lomefloxacin.
Gatifloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Gatifloxacin.
Norfloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Norfloxacin.
Levofloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Levofloxacin.
Gemifloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Gemifloxacin.
Ofloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Ofloxacin.
Sparfloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sparfloxacin.
Temafloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Temafloxacin.
Fleroxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Fleroxacin.
Technetium Tc-99m ciprofloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
Garenoxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Garenoxacin.
Nemonoxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Nemonoxacin.
Flumequine The therapeutic efficacy of Dulaglutide can be increased when used in combination with Flumequine.
Enrofloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Enrofloxacin.
Orbifloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Orbifloxacin.
Sarafloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sarafloxacin.
Difloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Difloxacin.
Pazufloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Pazufloxacin.
Prulifloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Prulifloxacin.
Delafloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Delafloxacin.
Sitafloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sitafloxacin.
Oxolinic acid The therapeutic efficacy of Dulaglutide can be increased when used in combination with Oxolinic acid.
Rufloxacin The therapeutic efficacy of Dulaglutide can be increased when used in combination with Rufloxacin.
Pipemidic acid The therapeutic efficacy of Dulaglutide can be increased when used in combination with Pipemidic acid.
Methyclothiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methyclothiazide.
Chlorthalidone The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorthalidone.
Bendroflumethiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bendroflumethiazide.
Metolazone The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone.
Benzthiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Benzthiazide.
Hydroflumethiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydroflumethiazide.
Indapamide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indapamide.
Chlorothiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorothiazide.
Hydrochlorothiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrochlorothiazide.
Trichlormethiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Trichlormethiazide.
Polythiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Polythiazide.
Quinethazone The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quinethazone.
Cyclopenthiazide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Cyclopenthiazide.
Epitizide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Epitizide.
Amitriptyline Amitriptyline may decrease the hypoglycemic activities of Dulaglutide.
Protriptyline Protriptyline may decrease the hypoglycemic activities of Dulaglutide.
Imipramine Imipramine may decrease the hypoglycemic activities of Dulaglutide.
Nortriptyline Nortriptyline may decrease the hypoglycemic activities of Dulaglutide.
Amoxapine Amoxapine may decrease the hypoglycemic activities of Dulaglutide.
Trimipramine Trimipramine may decrease the hypoglycemic activities of Dulaglutide.
Doxepin Doxepin may decrease the hypoglycemic activities of Dulaglutide.
Desipramine Desipramine may decrease the hypoglycemic activities of Dulaglutide.
Clomipramine Clomipramine may decrease the hypoglycemic activities of Dulaglutide.
Amineptine Amineptine may decrease the hypoglycemic activities of Dulaglutide.
Dimetacrine Dimetacrine may decrease the hypoglycemic activities of Dulaglutide.
Butriptyline Butriptyline may decrease the hypoglycemic activities of Dulaglutide.
Dosulepin Dosulepin may decrease the hypoglycemic activities of Dulaglutide.
Tianeptine Tianeptine may decrease the hypoglycemic activities of Dulaglutide.
Oxaprotiline Oxaprotiline may decrease the hypoglycemic activities of Dulaglutide.
Opipramol Opipramol may decrease the hypoglycemic activities of Dulaglutide.
Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Dulaglutide.
Dibenzepin Dibenzepin may decrease the hypoglycemic activities of Dulaglutide.
Quinupramine Quinupramine may decrease the hypoglycemic activities of Dulaglutide.
Melitracen Melitracen may decrease the hypoglycemic activities of Dulaglutide.
Lofepramine Lofepramine may decrease the hypoglycemic activities of Dulaglutide.
Iprindole Iprindole may decrease the hypoglycemic activities of Dulaglutide.
Imipramine oxide Imipramine oxide may decrease the hypoglycemic activities of Dulaglutide.
Glimepiride Dulaglutide may increase the hypoglycemic activities of Glimepiride.
Acetohexamide Dulaglutide may increase the hypoglycemic activities of Acetohexamide.

Target Protein

Glucagon-like peptide 1 receptor GLP1R

Referensi & Sumber

Artikel (PubMed)
  • PMID: 24373234
    Nadkarni P, Chepurny OG, Holz GG: Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23-65. doi: 10.1016/B978-0-12-800101-1.00002-8.
  • PMID: 25367716
    Sanford M: Dulaglutide: first global approval. Drugs. 2014 Nov;74(17):2097-103. doi: 10.1007/s40265-014-0320-7.
  • PMID: 27330280
    Amblee A: Mode of administration of dulaglutide: implications for treatment adherence. Patient Prefer Adherence. 2016 Jun 2;10:975-82. doi: 10.2147/PPA.S82866. eCollection 2016.
  • PMID: 26507721
    Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, de la Pena A: Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clin Pharmacokinet. 2016 May;55(5):625-34. doi: 10.1007/s40262-015-0338-3.
  • PMID: 26423061
    Burness CB, Scott LJ: Dulaglutide: A Review in Type 2 Diabetes. BioDrugs. 2015 Dec;29(6):407-18. doi: 10.1007/s40259-015-0143-4.
  • PMID: 27313432
    Smith LL, Mosley JF 2nd, Parke C, Brown J, Barris LS, Phan LD: Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist. P T. 2016 Jun;41(6):357-60.

Contoh Produk & Brand

Produk: 34 • International brands: 0
Produk
  • Trulicity
    Injection, solution • 0.75 mg/0.5mL • Subcutaneous • US • Approved
  • Trulicity
    Injection, solution • 1.5 mg/0.5mL • Subcutaneous • US • Approved
  • Trulicity
    Injection, solution • 1.5 mg/0.5mL • Subcutaneous • US • Approved
  • Trulicity
    Injection, solution • 0.75 mg/0.5mL • Subcutaneous • US • Approved
  • Trulicity
    Injection, solution • 0.75 mg/0.5mL • Subcutaneous • US • Approved
  • Trulicity
    Injection, solution • 1.5 mg/0.5mL • Subcutaneous • US • Approved
  • Trulicity
    Injection, solution • 3.0 mg/0.5mL • Subcutaneous • US • Approved
  • Trulicity
    Injection, solution • 4.5 mg/0.5mL • Subcutaneous • US • Approved
Menampilkan 8 dari 34 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul